U.S. Markets closed

Concert Pharmaceuticals, Inc. (CNCE)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
5.88+0.86 (+17.13%)
At close: 04:00PM EDT
6.04 +0.16 (+2.72%)
After hours: 07:56PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.50
Bid5.97 x 1300
Ask6.18 x 1000
Day's Range4.40 - 4.61
52 Week Range2.57 - 6.80
Avg. Volume295,461
Market Cap203.8M
Beta (5Y Monthly)0.38
PE Ratio (TTM)N/A
EPS (TTM)-1.97
Earnings DateFeb 23, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.08
  • Benzinga

    The Analyst Says 'Impressive Phase 3 Data Highlight Best-In-Class Opportunity' For Concert Pharma

    Concert Pharmaceuticals Inc (NASDAQ: CNCE) has released highly positive Phase 3 data for their alopecia areata drug CTP-543 from the THRIVE-AA1 trial. Mizuho says that the efficacy supports its view that CTP-543 potentially has best-in-class efficacy amongst the three main oral JAK inhibitors in late-stage development for alopecia areata (CTP-543, Eli Lilly And Co's (NYSE: LLY) Olumiant and Pfizer Inc's (NYSE: PFE) ritlecitinib). The analysts kept the Buy rating with a price target of $9 for the

  • Benzinga

    Concert Pharma's CTP-543 Shows Clinical Efficacy Against Scalp Hair Loss

    Concert Pharmaceuticals Inc (NASDAQ: CNCE) has announced topline results from its Phase 3 THRIVE-AA1 trial of CTP-543 in adult patients with moderate to severe alopecia areata (AA). AA is an autoimmune disorder resulting in patchy or complete scalp hair loss. The study's primary endpoint of the percentage of patients achieving an absolute Severity of Alopecia Tool (SALT) score of 20 or less at Week 24 of treatment was met with statistical significance in the 8 mg and 12 mg dose groups relative t

  • Business Wire

    Concert Pharmaceuticals Reports Positive Topline Results for First CTP-543 Phase 3 Clinical Trial in Alopecia Areata

    LEXINGTON, Mass., May 23, 2022--Concert's THRIVE-AA1 Phase 3 study in alopecia areata meets primary endpoint for scalp hair regrowth and key secondary endpoints at both doses.